Nasholm, Nicole
Revolution Medicines (United States)
6 papers on CoChatORCID 0000-0002-5451-4985
Most cited papers
- Verified
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
Holderfield, M., Lee, B. J., Jiang, J., Tomlinson, A., Seamon, K. J., Mira, A., Patrucco, E., Goodhart, G., Dilly, J., Gindin, Y., et al. (2024) · Nature
Protein Kinase Regulation and GTPase SignalingProtein Tyrosine Phosphatases
Cited by 369
- Verified
An expanded universe of cancer targets
Hahn, W. C., Bader, J. S., Braun, T. P., Califano, A., Clemons, P. A., Druker, B. J., Ewald, A. J., Fu, H., Jagu, S., Kemp, C. J., et al. (2021) · Cell
Cancer Genomics and DiagnosticsChromatin Remodeling and Cancer
Cited by 213
- Verified
Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma
Simonds, E. F., Lu, E. D., Badillo, O., Karimi, S., Liu, E. V., Tamaki, W., Rancan, C., Downey, K. M., Stultz, J., Sinha, M., et al. (2021) · Journal for ImmunoTherapy of Cancer
Cancer Immunotherapy and BiomarkersGlioma Diagnosis and Treatment
Cited by 119
- Verified
Abstract 3595: RMC-6291, a next-generation tri-complex KRASG12C(ON) inhibitor, outperforms KRASG12C(OFF) inhibitors in preclinical models of KRASG12C cancers
Nichols, R. J., Yang, Y. C., Cregg, J., Schulze, C. J., Wang, Z., Dua, R., Jiang, J., Garrenton, L. S., Nasholm, N., Bermingham, A., et al. (2022) · Cancer Research
Protein Kinase Regulation and GTPase SignalingLung Cancer Treatments and Mutations
Cited by 37
- Verified
Abstract 3597: Direct targeting of KRASG12X mutant cancers with RMC-6236, a first-in-class, RAS-selective, orally bioavailable, tri-complex RASMULTI(ON) inhibitor
Koltun, E. S., Rice, M. A., Gustafson, W. C., Wilds, D., Jiang, J., Lee, B. J., Wang, Z., Chang, S., Flagella, M., Mu, Y., et al. (2022) · Cancer Research
Protein Kinase Regulation and GTPase SignalingProtein Tyrosine Phosphatases
Cited by 34
- Verified
Direct targeting of RAS in pancreatic ductal adenocarcinoma with RMC-6236, a first-in-class, RAS-selective, orally bioavailable, tri-complex RASMULTI(ON) inhibitor.
Gustafson, W. C., Wildes, D., Rice, M. A., Lee, B. J., Jiang, J., Wang, Z., Chang, S., Flagella, M., Mu, Y., Dinglasan, N., et al. (2022) · Journal of Clinical Oncology
Protein Kinase Regulation and GTPase SignalingPancreatic and Hepatic Oncology Research
Cited by 28
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free